Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea · Delayed Price · Currency is KRW 10,300
+70 (0.68%)
At close: Apr 10, 2026
Daewon Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 605,435 | 598,162 | 526,952 | 478,885 | 354,176 |
Other Revenue | - | -0 | -0 | -0 | -0 |
| 605,435 | 598,162 | 526,952 | 478,885 | 354,176 | |
Revenue Growth (YoY) | 1.22% | 13.51% | 10.04% | 35.21% | 14.81% |
Cost of Revenue | 334,018 | 312,188 | 271,808 | 243,038 | 179,630 |
Gross Profit | 271,416 | 285,974 | 255,144 | 235,847 | 174,546 |
Selling, General & Admin | 233,974 | 226,957 | 198,507 | 173,719 | 144,585 |
Research & Development | 23,762 | 21,926 | 18,207 | 12,646 | - |
Amortization of Goodwill & Intangibles | 2,099 | 2,082 | 1,034 | 1,505 | 988.79 |
Other Operating Expenses | 3,305 | 3,242 | 2,951 | 2,320 | 8,009 |
Operating Expenses | 267,932 | 259,297 | 222,911 | 192,943 | 155,243 |
Operating Income | 3,484 | 26,677 | 32,233 | 42,904 | 19,303 |
Interest Expense | -7,221 | -9,306 | -4,614 | -3,683 | -2,078 |
Interest & Investment Income | 1,210 | 1,664 | 1,416 | 1,259 | 532.2 |
Earnings From Equity Investments | 684.26 | 704.2 | 509.42 | 860.08 | 382.62 |
Currency Exchange Gain (Loss) | 251.34 | 156.06 | 121.26 | 219.82 | 71.59 |
Other Non Operating Income (Expenses) | -4,455 | 1,354 | 672.88 | 23.15 | 906.98 |
EBT Excluding Unusual Items | -6,046 | 21,249 | 30,338 | 41,583 | 19,119 |
Gain (Loss) on Sale of Investments | 10,788 | -1,149 | -61.5 | -752.76 | -870.39 |
Gain (Loss) on Sale of Assets | -583.17 | -19.83 | 149.95 | 45.71 | -0.86 |
Asset Writedown | -1,240 | -3,921 | -4,597 | -2,154 | -1,111 |
Other Unusual Items | -373.17 | - | - | - | - |
Pretax Income | 2,545 | 16,159 | 25,830 | 38,722 | 17,136 |
Income Tax Expense | 4,749 | 6,055 | 2,367 | 8,065 | 10,525 |
Earnings From Continuing Operations | -2,204 | 10,104 | 23,463 | 30,657 | 6,611 |
Earnings From Discontinued Operations | -1,809 | -1,059 | - | - | - |
Net Income to Company | -4,013 | 9,045 | 23,463 | 30,657 | 6,611 |
Minority Interest in Earnings | 2,633 | 5,165 | 453.67 | 1,287 | 378.15 |
Net Income | -1,380 | 14,210 | 23,917 | 31,944 | 6,989 |
Net Income to Common | -1,380 | 14,210 | 23,917 | 31,944 | 6,989 |
Net Income Growth | - | -40.59% | -25.13% | 357.08% | -60.38% |
Shares Outstanding (Basic) | 21 | 21 | 21 | 21 | 21 |
Shares Outstanding (Diluted) | 21 | 21 | 22 | 22 | 21 |
Shares Change (YoY) | 0.67% | -1.71% | -0.98% | 3.09% | -0.58% |
EPS (Basic) | -64.37 | 667.43 | 1139.91 | 1509.75 | 329.36 |
EPS (Diluted) | -87.38 | 667.43 | 1110.44 | 1478.37 | 329.36 |
EPS Growth | - | -39.90% | -24.89% | 348.86% | -60.15% |
Free Cash Flow | 12,512 | -4,829 | 39,446 | 18,405 | 18,309 |
Free Cash Flow Per Share | 583.77 | -226.83 | 1821.12 | 841.34 | 862.87 |
Dividend Per Share | - | - | - | - | 194.175 |
Dividend Growth | - | - | - | - | 25.00% |
Gross Margin | 44.83% | 47.81% | 48.42% | 49.25% | 49.28% |
Operating Margin | 0.58% | 4.46% | 6.12% | 8.96% | 5.45% |
Profit Margin | -0.23% | 2.38% | 4.54% | 6.67% | 1.97% |
Free Cash Flow Margin | 2.07% | -0.81% | 7.49% | 3.84% | 5.17% |
EBITDA | 27,231 | 46,771 | 49,794 | 62,272 | 37,109 |
EBITDA Margin | 4.50% | 7.82% | 9.45% | 13.00% | 10.48% |
D&A For EBITDA | 23,747 | 20,095 | 17,561 | 19,368 | 17,805 |
EBIT | 3,484 | 26,677 | 32,233 | 42,904 | 19,303 |
EBIT Margin | 0.58% | 4.46% | 6.12% | 8.96% | 5.45% |
Effective Tax Rate | 186.59% | 37.47% | 9.16% | 20.83% | 61.42% |
Advertising Expenses | 35,370 | 33,923 | 29,701 | 27,199 | 26,272 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.